Efficacy of adjunctive Celecoxib in improvement of Obsessive-compulsive disorder

Phase 2

Conditions: Obsessive-compulsive disorder.
Obsessive-compulsive disorder

Registration Number: IRCT201512235280N21

Lead Sponsor: Vice chancellor for research of Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 40

Inclusion Criteria

Inclusion:
Patients were considered for participation in the project if they were met DSM-1V criteria for diagnosis of OCD. The diagnosis was confirmed by a psychiatrist based on structured interview ; A minimum score of 21 or above on the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS).
Exclusion:

The patients did not receive any Psychotropic medications such as selective serotonin reuptake inhibitors (SSRIs), tricyclic Antidepressants (TCAs), or monoamine oxide inhibitors for 4 weeks preceding entry into the trial Patients; they suffered from known autoimmune disease; bipolar I or bipolar II disorder; eating disorders; personality disorders; mental retardation; substance dependence or abuse; had a concurrent medical illness; history of seizures that would contraindicate use of the study medication; receiving ECT; peptic ulcers or a history of gastrointestinal bleeding; use of any medications identified as contra-indicated with COX-2 inhibitors.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Obsessive-compulsive disorder. Timepoint: baseline, 4, 8, 12 weeks. Method of measurement: Yale–Brown Obsessive–Compulsive Scale (Y-BOCS).;Depression. Timepoint: Baseline,12 th weeks. Method of measurement: Hamilton Depression Rating Scale.;Anxiety. Timepoint: Baseline,12 th weeks. Method of measurement: Hamilton Anxiety Rating Scale.;Illness severity. Timepoint: Baseline, 1, 2, 3,4 weeks. Method of measurement: Clinical Global Impression (CGI).

Secondary Outcome Measures